Skip to main content

Table 4 Cost inputs used in the model

From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

Costs VR-CAP R-CHOP Source
Drug costs per treatment cycle £4,426 £2,383 MIMS 2015 [31], eMIT 2014 [32]
Administration costs first treatment cycle £1,116 £381 NHS reference costs 2013–2014 [29]
Administration costs per subsequent treatment cycle £980 £245 NHS reference costs 2013–2014 [29]
Cost per 90 days of second-line treatment & administration £11,442 £11,665 MIMS 2015 [31], eMIT 2014 [32]
Cost of care at end of life £6,018 £6,018 Addicott, 2008 [45], Curtis, 2014 [30]